Scaling up chronic disease prevention interventions in lower- and middle-income countries

Annual Review of Public Health

Volumn 34, Issue , 2013, Pages 317-335

  Gaziano, Thomas A ^a,b   Pagidipati, Neha ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Medications; Noncommunicable diseases; Population and individual interventions; Primary and secondary prevention; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; POTASSIUM; SODIUM CHLORIDE; TRANS FATTY ACID;

BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; HEALTH CARE POLICY; HUMAN; HYPERTENSION; INCOME; ISCHEMIC HEART DISEASE; MASS SCREENING; PATENT; PHYSICAL ACTIVITY; POPULATION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK FACTOR; SALT INTAKE; SCALE UP; SECONDARY PREVENTION; SEDENTARY LIFESTYLE; SMOKING; SOCIAL STATUS;

CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; EXERCISE; HEALTH PROMOTION; HUMANS; RISK FACTORS; SMOKING; SODIUM CHLORIDE, DIETARY; TRANS FATTY ACIDS;

EID: 84875450372     PISSN: 01637525     EISSN: 15452093     Source Type: Book Series    
DOI: 10.1146/annurev-publhealth-031912-114402     Document Type: Review

References (117)

1. Aggarwal BB, Danda D, Gupta S, Gehlot P. 2009. Models for prevention and treatment of cancer: problems versus promises. Biochem. Pharmacol. 78:1083-94
2. Allison DB, Egan SK, Barraj LM, Caughman C, Infante M, Heimbach JT. 1999. Estimated intakes of trans fatty and other fatty acids in the US population. J. Am. Diet. Assoc. 99:166-74; quiz 175-76
3. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. 2007. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 370:2044-53
4. Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. 1999. Trans fatty acids and coronary heart disease. N. Engl. J. Med. 340:1994-98
5. Assmann G, Cullen P, Schulte H. 2002. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation 105:31015. Erratum. 2002. Circulation 105(7):900
6. Beall R, Kuhn R. 2012. Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis. PLoS Med. 9:e1001154
7. Bell AC, GeK, Popkin BM. 2002. The road to obesity or the path to prevention:motorized transportation and obesity in China. Obes. Res. 10:277-83
8. Bitton A, Gaziano TA. 2011. The cost-effectiveness of selective tobacco control policies in South Africa. In Soc. Gen. Intern. Med. Annu. Meet. Build. 21st Century Med. Through Educ., Res., Policy and Pract., 34th, Phoenix, AZ, pp. 353-54
9. Brown IJ, Tzoulaki I, Candeias V, Elliott P. 2009. Salt intakes around the world: implications for public health. Int. J. Epidemiol. 38:791-813
10. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. 2011. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull. World Health Organ. 89:412-21
11. Chaloupka FJ, Hu T-W, Warner KE, Jacobs R, Yurekli A. 2000. The taxation of tobacco products. See Ref. 42, pp. 237-72
12. China Salt Substit. Study Collab. Group. 2007. Salt substitution: a low-cost strategy for blood pressure control among rural Chinese. A randomized, controlled trial. J. Hypertens. 25:2011-18
13. Chobanian AV, Bakris GL, Black HR, CushmanWC, Green LA, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-52
14. Cohen JT, Neumann PJ, Weinstein MC. 2008. Does preventive care save money? Health economics and the presidential candidates. N. Engl. J. Med. 358:661-63
15. Colditz GA, Wei EK. 2012. Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality. Annu. Rev. Public Health 33:137-56
16. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, et al. 2003. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24:987-1003
17. Correa CM. 2006. Implications of bilateral free trade agreements on access to medicines. Bull. World Health Organ. 84:399-404
18. Elliott P, Stamler J, Nichols R, Dyer AR, Stamler R, et al. 1996. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. Br. Med. J. 312:1249-53
19. Eriksson KF, Lindgarde F. 1991. Prevention of type 2 (non-insulin- dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 34:891-98
20. Fairall LR, Zwarenstein M, Bateman ED, Bachmann M, Lombard C, et al. 2005. Effect of educational outreach to nurses on tuberculosis case detection and primary care of respiratory illness: pragmatic cluster randomised controlled trial. Br. Med. J. 331:750-54
21. FerrarioM, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, et al. 2005. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int. J. Epidemiol. 34:413-21
22. Fezeu L, Kengne AP, Balkau B, Awah PK, Mbanya J-C. 2009. Ten-year change in blood pressure levels and prevalence of hypertension in urban and rural Cameroon. J. Epidemiol. Community Health 64:360-65
23. Folsom AR, Chambless LE, BallantyneCM, Coresh J, HeissG, et al. 2006. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities study. Arch. Intern. Med. 166:1368-73
24. Food Stand. Agency. Dietary Sodium Levels Surveys, 22 July 2008. London: Food Stand. Agency. http://www.food.gov.uk/science/dietarysurveys/urinary
25. Ford ES, Capewell S. 2011. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu. Rev. Public Health 32:5-22
26. Gaziano TA. 2005. Cardiovascular disease in the developing world and its cost-effective management. Circulation 112:3547-53
27. Gaziano TA. 2007. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff. 26:13-24
28. Gaziano TA, Galea G, Reddy KS. 2007. Scaling up interventions for chronic disease prevention: the evidence. Lancet 370:1939-46
29. Gaziano TA, Opie LH, Weinstein MC. 2006. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 368:679-86
30. Gaziano TA, Steyn K, Cohen DJ, WeinsteinMC, Opie LH. 2005. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation 112:3569-76
31. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. 2008. Laboratory-based versus nonlaboratory- based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 371:923-31
32. Ghafoorunissa G. 2008. Role of trans fatty acids in health and challenges to their reduction in Indian foods. Asia Pac. J. Clin. Nutr. 17(Suppl. 1):212-15
33. Giugliano RP, Llevadot J, Wilcox RG, Gurfinkel EP, McCabe CH, et al. 2001. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur. Heart J. 22:1702-15
34. Guindon GE, Tobin S, Yach D. 2002. Trends and affordability of cigarette prices: ample room for tax increases and related health gains. Tob. Control 11:35-43
35. He FJ, MacGregor GA. 2002. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J. Hum. Hypertens. 16:761-70
36. Health Can. 2009. Trans Fat Monitoring Program. First Set of Trans Fat Monitoring Data. Ottawa Food Directorate, Health Products and Food Branch. Ottawa, ON: Health Can. http://www.hc-sc.gc.ca/fn-an/nutrition/gras-trans-fats/ tfa-age-tc-tm-eng.php
37. Hippisley-Cox J, Coupland C. 2005. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. Br. Med. J. 330:1059-63
38. Icks A, Haastert B, Trautner C, Giani G, Glaeske G, Hoffmann F. 2009. Incidence of lower-limb amputations in the diabetic compared to the non-diabetic population. findings from nationwide insurance data, Germany, 2005-2007. Exp. Clin. Endocrinol. Diabetes 117:500-4
39. Int. Diabetes Fed. (IDF). 2011. IDF Diabetes Atlas. The Global Burden. Brussels: IDF. 5th ed. http://www.idf.org/diabetesatlas/5e/the-global-burden
40. Jamison DT, Breman JG, Measham AR, Alleyne G, Cleason M, eds. et al. 2006. Disease Control Priorities in Developing Countries. New York: Oxford Univ. Press/World Bank
41. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. 2008. Cancer statistics, 2008. CA: A Cancer J. Clin. 58:71-96
42. Jha P, Chaloupka FJ, eds. 2000. Tobacco Control in Developing Countries. Oxford, UK: Oxford Univ. Press
43. Jha P, Chaloupka FJ, Moore J, Gajalakshmi V, Gupta PC, et al. 2006. Tobacco addiction. See Ref. 42, pp. 869-85
44. Jha P, Ranson MK, Nguyen SN, Yach D. 2002. Estimates of global and regional smoking prevalence in 1995, by age and sex. Am. J. Public Health 92:1002-6
45. John RM. 2008. Price elasticity estimates for tobacco products in India. Health Policy Plan 23:200-9
46. Kenkel D, Chen L. 2000. Consumer information and tobacco use. See Ref. 42, pp. 177-214
47. Kerry VB, Lee K. 2007. TRIPS, theDohaDeclaration and paragraph 6 decision: What are the remaining steps for protecting access to medicines? Glob. Health 3:3
48. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346:393-403
49. Kramer JM, Newby LK, Chang WC, Simes RJ, Van de Werf F, et al. 2003. International variation in the use of evidence-based medicines for acute coronary syndromes. Eur. Heart J. 24:2133-41
50. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. 1995. Cost-effectiveness analysis in heart disease, part III: ischemia, congestive heart failure, and arrhythmias. Prog. Cardiovasc. Dis. 37:307-46
51. Lee JM, Liao DS, Ye CY, Liao WZ. 2005. Effect of cigarette tax increase on cigarette consumption in Taiwan. Tob. Control 14(Suppl. 1):i71-75
52. LeeWL, Cheung AM, CapeD, Zinman B. 2000. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 23:962-68
53. Leth T, Jensen HG, Mikkelsen AA, Bysted A. 2006. The effect of the regulation on trans fatty acid content in Danish food. Atheroscler. Suppl. 7:53-56
54. Levy AR, Briggs AH, Demers C, OBrien BJ. 2001. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Am. Heart J. 142:537-43
55. Li N, Prescott J, Wu Y, Barzi F, Yu X, et al. 2009. The effects of a reduced-sodium, high-potassium salt substitute on food taste and acceptability in rural northern China. Br. J. Nutr. 101:1088-93
56. Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, et al. 2007. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 370:2054-62
57. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. 2010. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 122:2078-88
58. Lybecker KM, Fowler E. 2009. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules. J. Law Med. Ethics 37:222-39
59. Malach M, Imperato PJ. 2006. Acute myocardial infarction and acute coronary syndrome: then and now (1950-2005). Prev. Cardiol. 9:228-34
60. Mathers CD, Stein C, Ma Fat D, Rao C, Inoue M, Tomijima N, et al. 2002. Global Burden of Disease 2000: Version 2 Methods and Results. GPE Discuss. Pap. No. 50. Geneva:WHO
61. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, et al. 2005. WHO study on prevention of recurrences of myocardial infarction and stroke (WHO-PREMISE). Bull. World Health Organ. 83:820-29
62. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, et al. 2007. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull. World Health Organ. 85:279-88
63. Mendis S, Lindholm LH, Mancia G, Whitworth J, AldermanM, et al. 2007. WorldHealthOrganization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J. Hypertens. 25:1578-82
64. Mensink RP, Zock PL, Kester AD, Katan MB. 2003. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am. J. Clin. Nutr. 77:1146-55
65. Morrison AC, Ness RB. 2011. Sodium intake and cardiovascular disease. Annu. Rev. Public Health 32:71-90
66. Mozaffarian D, AbdollahiM, Campos H, Houshiarrad A, Willett WC. 2007. Consumption of trans fats and estimated effects on coronary heart disease in Iran. Eur. J. Clin. Nutr. 61:1004-10
67. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. 2006. Trans fatty acids and cardiovascular disease. N. Engl. J. Med. 354:1601-13
68. Narayan KMV, Zhang P, Kanaya AM, WilliamsDE, Engelgau MM, et al. 2006. Diabetes: the pandemic and potential solutions. See Ref. 40, pp. 591-604
69. Novotny TE, Cohen JC, Yurekli A, Sweaner D, de Beyer J. 2000. Smoking cessation and nicotinereplacement therapies. See Ref. 40, pp. 287-310
70. Nugent RA, Feigl AB. 2010. Where have all the donors gone? Scarce donor funding for non-communicable diseases. Work. Pap. 228. Cent. Glob. Dev., Washington, DC
71. ODonnell MJ, Yusuf S, Mente A, Gao P, Mann JF, et al. 2011. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 306:2229-38
72. Oomen CM, Ocke MC, Feskens EJ, van Erp-Baart MA, Kok FJ, Kromhout D. 2001. Association between trans fatty acid intake and 10-year risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-based study. Lancet 357:746-51
73. Orlandini A, Diaz R, Wojdyla D, Pieper K, Van de Werf F, et al. 2006. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur. Heart J. 27:527-33
74. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, et al. 1997. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-44
75. Pandya A, WeinsteinMC, Gaziano TA. 2011. A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PLoS One 6:e20416
76. Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P. 2008. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: Is sodium an old enemy or a new friend? Clin. Sci. 114:221-30
77. Paterna S, Parrinello G, Cannizzaro S, Fasullo S, Torres D, et al. 2009. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. Am. J. Cardiol. 103:93-102
78. Pérez-Ferrer C, Lock K, Rivera JA. 2010. Learning from international policies on trans fatty acids to reduce cardiovascular disease in low- and middle-income countries, usingMexico as a case study. Health Policy Plan. 25:39-49
79. Pezzella AT. 2006. Global statistics/outcomes. J. Thorac. Cardiovasc. Surg. 132:726
80. Pietinen P, Ascherio A, Korhonen P, Hartman AM, Willett WC, et al. 1997. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am. J. Epidemiol. 145:876-87
81. RawM, McNeill A, West R. 1999. Smoking cessation: evidence based recommendations for the healthcare system. Br. Med. J. 318:182-85
82. Ribeiro AL, Gagliardi SP, Nogueira JL, Silveira LM, Colosimo EA, Lopes do Nascimento CA. 2006. Mortality related to cardiac surgery in Brazil, 2000-2003. J. Thorac. Cardiovasc. Surg. 131:907-9
83. Ridker PM, Buring JE, Rifai N, Cook NR. 2007. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611-19
84. Ruger JP, Lazar CM. 2012. Economic evaluation of pharmaco- and behavioral therapies for smoking cessation: a critical and systematic review of empirical research. Annu. Rev. Public Health 33:279-305
85. Saffer H, Chaloupka F. 2000. The effect of tobacco advertising bans on tobacco consumption. J. Health Econ. 19:1117-37
86. Sikri N, Bardia A. 2007. A history of streptokinase use in acute myocardial infarction. Tex. Heart Inst. J. 34:318-27
87. Smith RD, Correa C, Oh C. 2009. Trade, TRIPS, and pharmaceuticals. Lancet 373:684-91
88. Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. 2010. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. Ann. Intern. Med. 152:481-87, W170-73
89. Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M. 1989. INTERSALT study findings. Public health and medical care implications. Hypertension 14:570-77
90. Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, et al. 2002. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am. J. Cardiol. 90:358-63
91. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerová J, et al. 2011. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA 305:1777-85
92. Teegala SM, Willett WC, Mozaffarian D. 2009. Consumption and health effects of trans fatty acids: a review. J. AOAC Int. 92:1250-57
93. Thom S, Field J, PoulterN, Patel A, PrabhakaranD, et al. 2012. Use of aMultidrug Pill in ReducingCardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur. J. Prev. Cardiol. 4:4
94. Townsend J. 1993. Policies to halve smoking deaths. Addiction 88:37-46
95. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, et al. 2001. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J.Med. 344:1343-50
96. USDep. HealthHum. Serv. (DHHS). 2000. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, GA: US DHHS, Public Health Serv., Cent. Dis. Control, Off. Smok. Health. http://www.cdc.gov/tobacco/data-statistics/sgr/2000/ complete-report/pdfs/fullreport.pdf
97. van Mourik MS, Cameron A, Ewen M, Laing RO. 2010. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc. Disord. 10:25
98. Van Walbeek C. 2003. Tobacco Excise Taxation in South Africa. Geneva:WHO
99. Wald NJ, Law MR. 2003. A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. 326:1419
100. Wang TJ, Gona P, LarsonMG, Tofler GH, Levy D, et al. 2006. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355:2631-39
101. Ware JH. 2006. The limitations of risk factors as prognostic tools. N. Engl. J. Med. 355:2615-17
102. Weber A, Mills L. 2010. A one-time-only combination: emergency medicine exports and the TRIPS agreement under Canadas access to medicines regime. Health Hum. Rights 12:109-22
103. WeinsteinMC, Stason WB. 1985. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu. Rev. Public Health 6:41-63
104. Willett WC, Koplan JP, Nugent R, Dusenbury C, Puska P, Gaziano TA. 2006. Prevention of chronic disease by means of diet and lifestyle changes (table 44.2). See Ref. 40, pp. 833-50
105. Wilson PW, DAgostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. 1998. Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-47
106. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, et al. 2004. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43:10-17
107. Woolery T, Asma S, Sharp D. 2000. Clean indoor-air laws and youth access. See Ref. 42, pp. 273-86
108. World Health Organ. (WHO). 2005. The Health Benefits of Physical Activity in Developing Countries: A Review of the Epidemiological Evidence. Geneva:WHO
109. World Health Organ. (WHO). 2005. Review of Best Practice in Interventions to Promote Physical Activity in Developing Countries. WHO Workshop Phys. Act. Public Health. Geneva: WHO. http://www.who.int/dietphysicalactivity/ bestpracticePA2008.pdf
110. WorldHealthOrgan. (WHO). 2011. Diabetes. Fact Sheet No. 312. Geneva:WHO. http://www.who.int/mediacentre/factsheets/fs312/en/index.html
111. World Health Organ. (WHO)/Food Agric. Organ. (FAO). 2003. Diet, Nutrition and the Prevention of Chronic Diseases. Rep. Jt. WHO/FAO Expert Consult. Tech. Rep. Ser. 916. Geneva: WHO. http://whqlibdoc.who.int/trs/who-trs-916.pdf
112. Yusuf S. 2002. Two decades of progress in preventing vascular disease. Lancet 360:2-3
113. Yusuf S. 2007. Heart Outcomes Prevention Evaluation-3 (HOPE-3). Clinical Trials.gov identif. NCT00468923, Popul. Health Res. Inst. http://clinicaltrials. gov/ct2/show/NCT00468923?term= NCT00468923&rank=1
114. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, et al. 2011. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378:1231-43
115. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, et al. 2009. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 373:1341-51
116. Yusuf S, Pais P, Xavier D. 2009. The Indian Polycap Study (TIPS): authors reply. Lancet 374:782
117. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, et al. 2010. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87:293-301